Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment
Authors:
Open Access
- 19 January 2023
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 41 (3) , 295-306
Abstract
Background The disutilities of adverse events (AEs) are important inputs for cost-utility analysis (CUA), reflecting the impacts of AEs on health outcomes. Health technology assessment institutions and scholars have proposed recommendations for applying disutility values in economic evaluations. Objectives This study aimed to identify the current use of disutilities of AEs as model parameters in the CUA of cancer drug therapy and to compare the discrepancies between the use of disutilities and published recommendations. Methods A systematic search was conducted on the PubMed, Web of Science, and Cochrane Library databases, as well as the official websites of the National Institute for Health and Care Research (NIHR), the Institute for Clinical and Economic Review (ICER), the Institute for Quality and Efficiency in Health Care (IQWiG), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Centre for Reviews and Dissemination (CRD) for CUAs of drug therapy for cancer published in English from January 2019 to April 2022. Information about the use of disutilities of AEs (whether and how disutilities were used, or why they were not used) in selected studies was extracted and compared with published recommendations. Descriptive analyses were used to summarize the results. Results A total of 467 CUAs were included, 54% (254/467) of which included disutilities of AEs in their model. The proportion that included these disutilities increased from 2019 to 2021, ranging from 47% (51/107) to 61% (116/190). Only 6% (15/254) of the CUAs using disutilities of AEs considered all five recommendations about the justification for inclusion and exclusion, description of values and sources, grades of AEs, calculation, and uncertainty analyses. Only 15% (72/467) provided a clear justification for inclusion and exclusion of disutilities of AEs, and 7% (17/254) did not provide values or sources. In total, 69% (175/254) of the analyses focused on AEs of grade 3 or greater, and 11% (28/254) applied utility decrements for grades 1 and 2. Disutilities of AEs were generally calculated using the incidence rates, which were clearly stated in 49% (65/132) of the analyses. Uncertainty analyses were conducted in 84% (214/254) of the CUAs. Conclusions The current use of disutilities of AEs in CUAs shows some discrepancies with recommendations proposed in the literature. One is that detailed information about the use of disutilities of AEs was not reported and the other is that essential methods to analyze the impact of AEs on quality-adjusted life-years were not thoroughly conducted. Therefore, it is suggested that researchers should attach importance to the impact of AEs on health-related quality of life. Furthermore, an application process was developed for the disutilities of AEs to remind and guide researchers to correctly use the disutilities of AEs as parameters in the decision-analytic model.Keywords
This publication has 58 references indexed in Scilit:
- Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)Journal of Medical Economics, 2019
- Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced MelanomaImmunotherapy, 2018
- Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United StatesPharmacoEconomics, 2018
- Gains in health utility associated with urinary catheter innovationsMedical Devices: Evidence and Research, 2018
- Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertensionPatient Preference and Adherence, 2018
- Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force ReportValue in Health, 2016
- Disutility of Illness for Caregivers and Families: A Systematic Review of the LiteraturePharmacoEconomics, 2013
- Using Health State Utility Values in Models Exploring the Cost-Effectiveness of Health TechnologiesValue in Health, 2012
- Are adverse effects incorporated in economic models? A survey of current practiceInternational Journal of Technology Assessment in Health Care, 2010
- Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHESJournal of Managed Care Pharmacy, 2003